natgillin/translations-raw huggingface dataset:
Lesinurad does not accumulate following multiple doses. 
Lesinurad se po večkratnih odmerkih ne kopiči.
There is no specific treatment in the event of an overdose, and symptoms of overdose are not established. 
Specifičnega zdravljenja za preveliko odmerjanje ni in simptomi prevelikega odmerjanja niso ugotovljeni.
It is unclear if metabolite plasma exposures are minimal. 
Ali je izpostavljenost presnovkom v plazmi minimalna, ni jasno.
If you forget to take Zurampic 
Če ste pozabili vzeti zdravilo Zurampic
Zurampic tablets contain lactose (a type of sugar). 
Zdravilo Zurampic tablete vsebuje laktozo (vrsto sladkorja).
Patients should be informed that failure to follow these instructions may increase the risk of renal events (see section 4.4). 
Bolnike je treba opozoriti, da lahko neupoštevanje teh navodil poveča tveganje za ledvične dogodke (glejte poglavje 4.4).
Following administration of a single oral dose of lesinurad in either the fed or fasted state, maximum plasma concentrations (Cmax) were attained within 1 to 4 hours. 
Po uporabi enega peroralnega odmerka lesinurada na poln želodec ali na tešče je bila največja koncentracija v plazmi (Cmax) dosežena v 1 do 4 urah.
In vitro assessment of interactions 
Ocena medsebojnih delovanj in vitro
Tablets are engraved with “LES200” on one side. 
Tablete imajo na eni strani vtisnjeno oznako “LES200”.
For cardiovascular patients in a stable condition, the benefit/risk balance should be assessed for each individual patient on an ongoing basis, taking into account the benefits of lowering urate levels versus a potential increase in cardiac risk (see section 4.8). 
Pri srčno-žilnih bolnikih v stabilnem stanju je treba za vsakega bolnika posamezno sproti ocenjevati ravnovesje koristi in tveganj ter pri tem upoštevati koristi znižanja koncentracije urata v primerjavi z možnim povečanjem tveganja za srčne bolezni (glejte poglavje 4.8).
Based on its mechanism of action, lesinurad may not be effective in these patients (see section 5.1). 
Zaradi mehanizma delovanja lesinurada je možno, da pri teh bolnikih ne bo učinkovit (glejte poglavje 5.1).
Sixty-six percent of patients had mild or moderate renal impairment. 
Šestinšestdeset odstotkov bolnikov je imelo blago ali zmerno okvaro ledvic.
Lesinurad is a mild to moderate inducer of CYP3A (see section 4.5). 
Lesinurad je blag do zmeren induktor CYP3A (glejte poglavje 4.5).
An induction effect of lesinurad should be anticipated after 2 to 3 weeks of continuous co-administration of Zurampic. 
Indukcijski učinek lesinurada je treba pričakovati po 2 do 3 tednih nepretrgane sočasne uporabe zdravila Zurampic.
Testing for the target serum uric acid level may be performed as early as 4 weeks after initiating Zurampic treatment. 
Preiskavo glede doseganja ciljne koncentracije sečne kisline v serumu je mogoče opraviti že 4 tedne po uvedbi zdravila Zurampic.
Therefore, it is recommended that patients are monitored for reduced efficacy of CYP2B6 substrates (e.g. bupropion, efavirenz) when co-administered with Zurampic. 
Zato je bolnike priporočljivo nadzirati glede zmanjšane učinkovitosti substratov CYP2B6 (npr. bupropiona, efavirenza), uporabljanih sočasno z zdravilom Zurampic.
All studies were of 12 months duration and patients received prophylaxis for gout flares with colchicine or NSAIDs during the first 5 months of lesinurad treatment. 
Vse študije so trajale 12 mesecev, bolniki pa so v prvih petih mesecih zdravljenja z lesinuradom prejemali kolhicin ali NSAID za profilakso napadov protina.
Secondary hyperuricaemia 
Sekundarna hiperurikemija
No dose adjustment is necessary based on age (see section 5.2); however, elderly patients are more likely to have decreased renal function (see dosing recommendations for renal impairment). 
Odmerka ni treba prilagoditi glede na starost (glejte poglavje 5.2), vendar pa je pri starejših bolnikih verjetnejše zmanjšano delovanje ledvic (glejte priporočila za odmerjanje pri okvari ledvic).
Across both studies, 61% of patients had mild or moderate renal impairment and 19% had tophi at baseline. 
V obeh študijah je imelo 61 % bolnikov blago ali zmerno okvaro ledvic in 19 % jih je imelo tofe izhodiščno.
2Q 2019 
2. četrtletje leta 2019
Within 7 days following single dosing of radiolabelled lesinurad, 63% of administered radioactive dose was recovered in urine and 32% of administered radioactive dose was recovered in faeces. 
V 7 dneh po enkratnem odmerku radioaktivno označenega lesinurada se je 63 % uporabljenega radioaktivnega odmerka pojavilo v urinu, 32 % pa v blatu.
Mean plasma-to-blood ratios of lesinurad AUC and Cmax were approximately 1.8, indicating that radioactivity was largely contained in the plasma space and did not penetrate or partition extensively into red blood cells. 
Povprečno razmerje AUC in Cmax lesinurada v plazmi in krvi je bilo približno 1,8; to kaže, da se je radioaktivnost v veliki meri zadržala v plazemskem prostoru in ni v veliki meri prodirala ali se porazdelila v eritrocite.
In addition, lesinurad is an in vitro inducer of CYP2B6 and CYP3A via CAR/PXR. 
Poleg tega lesinurad in vitro inducira CYP2B6 in CYP3A preko CAR/PXR.
Other medicines and Zurampic 
Druga zdravila in zdravilo Zurampic
Your doctor may ask you to have tests to check how your kidneys are working. 
Zdravnik vas bo morda napotil na preiskave za preverjanje delovanja ledvic.
Lesinurad is rapidly absorbed after oral administration. 
Lesinurad se po peroralni uporabi hitro absorbira.
Based on in vitro data, lesinurad may be a mild inducer of CYP2B6 but this interaction has not been studied clinically. 
Glede na podatke in vitro lesinurad morda blago inducira CYP2B6, vendar to medsebojno delovanje ni klinično raziskano.
The lack of an observed interaction could be due to the combination of the induction of CYP2C9 and inhibition of OATP1B1 and 1B3. 
Odsotnost opaženega medsebojnega delovanja je lahko posledica kombinacije indukcije CYP2C9 in zavrtja OATP1B1 in 1B3.
The possibility of reduced efficacy of concomitant medicinal products that are CYP3A substrates should be considered and their efficacy (e.g. blood pressure and cholesterol levels) should be monitored (see section 4.4). 
Upoštevati je treba možnost manjše učinkovitosti sočasnih zdravil, ki so substrati CYP3A, in treba je nadzirati njihovo učinkovitost (npr. krvni tlak in koncentracijo holesterola) (glejte poglavje 4.4).
Fluconazole, a moderate CYP2C9 inhibitor, increased lesinurad AUC (56%) and Cmax (38%), as well as the amount of lesinurad excreted unchanged in urine. 
Flukonazol, zmeren zaviralec CYP2C9, je povečal AUC lesinurada (56 %) in njegovo Cmax (38 %), pa tudi količino lesinurada, ki se je nespremenjen izločil v urinu.
There was no apparent influence of the fat content in the meal on the pharmacokinetics of lesinurad. 
Vsebnost maščob v obroku ni opazno vplivala na farmakokinetiko lesinurada.
Zurampic should not be used as monotherapy or at doses above the recommended dose. 
Zdravila Zurampic se ne sme uporabljati za samostojno zdravljenje ali v odmerkih, večjih od priporočenih.
Your doctor may tell you to restart treatment with Zurampic when your kidney function improves. 
Zdravnik vam lahko naroči, da znova začnete jemati zdravilo Zurampic, ko se vam delovanje ledvic izboljša.
What Zurampic is and what it is used for What you need to know before you take Zurampic How to take Zurampic 
Kaj je zdravilo Zurampic in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Zurampic Kako jemati zdravilo Zurampic Možni neželeni učinki
In patients with tophi or persistent symptoms, the target is less than 5 mg/dL (300 µmol/L). 
Pri bolnikih s tofi ali perzistentnimi simptomi je ciljna koncentracija manj kot 5 mg/dl (300 µmol/l).
Your doctor may consider stopping Zurampic if your blood tests indicate changes in how your kidneys are working (blood creatinine levels increase) or if you experience symptoms of kidney problems. 
Zdravnik bo morda razmislil o prenehanju zdravljenja z zdravilom Zurampic, če preiskave krvi pokažejo spremenjeno delovanje ledvic (zvišanje koncentracije kreatinina v krvi), ali če se vam pojavijo simptomi težav z ledvicami.
Placebo + febuxostat 80 mg N=51 
Placebo + 80 mg febuksostata N = 51
By lowering the amount of uric acid in the blood, Zurampic stops this accumulation and may prevent further joint damage. 
Z znižanjem količine sečne kisline v krvi zdravilo Zurampic ustavi to kopičenje in lahko prepreči nadaljnjo okvaro sklepov.
In clinical trials, most adverse reactions were mild or moderate in intensity and resolved while continuing Zurampic therapy. 
V kliničnih preskušanjih je bila večina neželenih učinkov blagih ali zmernih in so med nadaljevanjem zdravljenja z zdravilom Zurampic izginili.
The serious adverse reactions renal failure, renal impairment and nephrolithiasis have occurred uncommonly (less than 1 case per 100 patients) (see Table 1). 
Resni neželeni učinki (odpoved ledvic, okvara ledvic in nefrolitiaza) so se pojavljali občasno (manj kot 1 primer na 100 bolnikov) (glejte preglednico 1).
Tablet core hypromellose microcrystalline cellulose lactose monohydrate crospovidone type A magnesium stearate 
Jedro tablete hipromeloza mikrokristalna celuloza laktoza monohidrat krospovidon vrsta A magnezijev stearat
Gastro-oesophageal reflux disease 
Bolezni prebavil gastroezofagealna refluksna bolezen
Therefore, it is recommended that Zurampic should be used with caution in patients taking moderate inhibitors of CYP2C9. 
Zato je priporočljivo zdravilo Zurampic previdno uporabljati pri bolnikih, ki jemljejo zmerne zaviralce CYP2C9.
Continuous treatment with Zurampic decreases the frequency of gout flares. 
Trajno zdravljenje z zdravilom Zurampic zmanjša pogostnost napadov protina.
Data from the long-term extension studies until 24 months revealed a renal safety profile consistent with that observed in the placebocontrolled studies. 
Ledvične varnostne značilnosti na podlagi podatkov dolgoročnih podaljšanj študij do 24 mesecev se skladajo z varnostnimi značilnostmi, ugotovljenimi v študijah, kontroliranih s placebom.
Inhibitors of microsomal Epoxide Hydrolase (mEH) (e.g. valproic acid, valpromide) may interfere with the metabolism of lesinurad. 
Zaviralci mikrosomalne epoksid-hidrolaze (mEH - microsomal Epoxide Hydrolase) (npr. valprojska kislina, valpromid) lahko ovirajo presnovo lesinurada.
The elimination half-life (t½) of lesinurad was approximately 5 hours following a single dose. 
Eliminacijski razpolovni čas (t½) lesinurada po enkratnem odmerku je bil približno 5 ur.
Zurampic may cause serious kidney problems (see section 4), which occur more frequently if Zurampic is taken alone (see section 3). 
Zdravilo Zurampic lahko povzroči resne težave z ledvicami (glejte poglavje 4), ki so pogostejše, če zdravilo Zurampic jemljete samostojno (glejte poglavje 3).
Renal function should be evaluated prior to initiation of Zurampic and monitored periodically thereafter, e.g. 4 times per year, based on clinical considerations, such as baseline renal function, volume depletion, concurrent illness or concomitant medications. 
Delovanje ledvic je treba oceniti pred uvedbo zdravila Zurampic in ga kontrolirati redno med zdravljenjem, npr. 4-krat na leto glede na klinične okoliščine, npr. izhodiščno delovanje ledvic, hipovolemijo, sočasne bolezni ali sočasna zdravila.
The most commonly reported adverse reactions during treatment with Zurampic 200 mg are influenza, gastro-oesophageal reflux disease, headache and blood creatinine increased. 
Najpogosteje zabeleženi neželeni učinki med zdravljenjem z 200 mg zdravila Zurampic so gripa, gastroezofagealna refluksna bolezen, glavobol in zvišanje kreatinina v krvi.
Failure to follow these instructions may increase the risk of kidney side effects. 
Neupoštevanje teh navodil lahko poveča tveganje za neželene učinke na ledvicah.
Based on interaction studies in healthy subjects or gout patients, Zurampic does not have clinically significant interactions with NSAIDs (naproxen and indomethacin), colchicine, repaglinide, tolbutamide, febuxostat or allopurinol. 
Na podlagi študij medsebojnega delovanja pri zdravih osebah in bolnikih s protinom zdravilo Zurampic nima klinično pomembnih medsebojnih delovanj z NSAID (naproksen in indometacin), kolhicinom, repaglinidom, tolbutamidom, febuksostatom in alopurinolom.
The recommended dose is 1 tablet of 200 mg once a day in the morning. 
Priporočeni odmerek je ena 200-mg tableta enkrat na dan, zjutraj.
In the long-term uncontrolled extension trials, the rates of gout flares requiring treatment further decreased in the 60% of subjects who entered the extension studies and continued treatment with Zurampic 200 mg in combination with allopurinol or febuxostat for up to an additional year of treatment. 
V dolgoročnih nekontroliranih podaljšanjih študij so se deleži napadov protina, ki so zahtevali zdravljenje, dodatno zmanjšali pri 60 % bolnikov, ki so vstopili v podaljšane študije in nadaljevali zdravljenje z 200 mg zdravila Zurampic v kombinaciji z alopurinolom ali febuksostatom v obdobju do enega dodatnega leta zdravljenja.
The medicine is still working to lower uric acid. 
Zdravilo še vedno deluje in znižuje sečno kislino.
In an interaction study conducted in healthy subjects with multiple doses of Zurampic 400 mg and single dose warfarin (25 mg), lesinurad led to a decrease in exposure of R-warfarin (the less active enantiomer) and had no effect on the exposure of S-warfarin (the more active enantiomer). 
V študiji medsebojnega delovanja pri zdravih osebah, ki so dobile več odmerkov zdravila Zurampic 400 mg in en odmerek varfarina (25 mg), je lesinurad zmanjšal izpostavljenost R-varfarinu (manj aktivnemu enantiomeru) in ni vplival na izpostavljenost S-varfarinu (bolj aktivnemu enantiomeru).
After continued treatment of up to 24 months on Zurampic 200 mg in combination with febuxostat, the proportion of subjects who experienced complete resolution of at least one target tophus increased to 53% of subjects. 
Po nadaljevanju zdravljenja z 200 mg zdravila Zurampic v kombinaciji s febuksostatom do 24 mesecev se je delež bolnikov s popolnim izginotjem vsaj enega ciljnega tofa povečal na 53 % bolnikov.
Zurampic has not been studied in patients with severe hepatic impairment; therefore, dose recommendations cannot be given. 
Pri bolnikih s hudo okvaro jeter zdravilo Zurampic ni bilo raziskano, zato priporočil za odmerjanje ni mogoče dati.
The recommended minimum dose of allopurinol is 300 mg, or 200 mg for patients with moderate renal impairment (creatinine clearance [CrCL] of 30-59 mL/min). 
Priporočeni minimalni odmerek alopurinola je 300 mg oz. 200 mg pri bolnikih z zmerno okvaro ledvic (očistek kreatinina od 30 do 59 ml/min).
Patients known to be CYP2C9 poor metabolisers should be treated with caution, as the potential risk of renal-related adverse effects may be increased (see sections 4.8 and 5.2). 
Bolnike, ki so slabi metabolizatorji s CYP2C9, je treba zdraviti previdno, ker imajo lahko večje tveganje za neželene učinke na ledvicah (glejte poglavji 4.8 in 5.2).
Renal failure** Renal impairment Nephrolithiasis 
Bolezni sečil odpoved ledvic** okvara ledvic nefrolitiaza
HMG-CoA reductase inhibitors that are sensitive CYP3A substrates may interact with lesinurad. 
Zaviralci reduktaze HMG-CoA, ki so občutljivi substrati CYP3A lahko medsebojno delujejo z lesinuradom.
The ratio of atropisomer 1 to atropisomer 2 AUC(0-24) was 44:56 because atropisomer 1 undergoes more extensive metabolism than atropisomer 2, causing atropisomer 1 to have lower plasma exposure than atropisomer 2. 
Razmerje AUC(0-24) atropizomera 1 in atropizomera 2 je bilo 44:56, ker je atropizomer 1 podvržen izdatnejši presnovi kot atropizomer 2, zato je izpostavljenost atropizomeru 1 v plazmi manjša kot izpostavljenost atropizomeru 2.
Caution should be used when treating these patients with Zurampic. 
Pri teh bolnikih je treba zdravilo Zurampic uporabljati previdno.
In interaction studies conducted in healthy subjects with Zurampic and CYP3A substrates, lesinurad reduced the plasma concentrations of sildenafil and amlodipine. 
V študijah medsebojnih delovanj zdravila Zurampic in substratov CYP3A pri zdravih osebah je lesinurad zmanjšal koncentracijo sildenafila in amlodipina v plazmi.
The effect of CYP2C9 genotype on the pharmacokinetics of lesinurad was studied in 8 healthy subjects and 59 patients with gout following daily dosing of lesinurad ranging from 200 mg to 600 mg in the absence or presence of a xanthine oxidase inhibitor. 
Vpliv genotipa CYP2C9 na farmakokinetiko lesinurada so raziskali pri 8 zdravih osebah in 59 bolnikih s protinom po vsakodnevnem jemanju lesinurada v odmerkih od 200 do 600 mg v prisotnosti in odsotnosti zaviralca ksantin-oksidaze.
The mean steady state volume of distribution of lesinurad was approximately 20 L following intravenous dosing. 
Povprečni volumen porazdelitve lesinurada v stanju dinamičnega ravnovesja je bil po intravenski uporabi približno 20 litrov.
The recommended dose of Zurampic is 200 mg once daily in the morning. 
Priporočeni odmerek zdravila Zurampic je 200 mg enkrat na dan zjutraj.
Common - may affect up to 1 in 10 people - flu (influenza), - headache, - increase in the amount of creatinine in your blood -shown in tests, - heartburn(acid reflux). 
Pogosti - pojavijo se lahko pri največ 1 od 10 bolnikov - gripa (influenca), - glavobol, - povečanje količine kreatinina v krvi - pokaže se na krvnih preiskavah, - zgaga (refluks kisline).
Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable when Zurampic is co-administered. 
Hormonski kontraceptivi, vključno s tabletami, injekcijami, transdermalnimi oblikami in vsadki, so med sočasno uporabo z zdravilom Zurampic lahko nezanesljivi.
Pack sizes of 10, 28, 30, 98 in non-perforated blisters. 
Velikosti pakiranj z 10, 28, 30, 98 filmsko obloženimi tabletami v neperforiranih pretisnih omotih.
Rare - may affect up to 1 in 1000 people - skin reactions, including redness, itchy skin, lumpy rash (hives) and skin rash on exposure to sunshine. 
Redki - pojavijo se lahko pri največ 1 od 1.000 bolnikov - kožne reakcije, vključno s pordelostjo, srbenjem, dvignjenim izpuščajem (koprivnico) in izpuščajem na koži po izpostavljenosti soncu.
Zurampic contains the active ingredient lesinurad and is used to treat gout in adult patients by lowering the levels of uric acid in the blood. 
Zdravilo Zurampic vsebuje zdravilno učinkovino lesinurad in se uporablja za zdravljenje protina pri odraslih bolnikih, ker zniža raven sečne kisline v krvi.
If this happens, keep taking Zurampic and talk to your doctor or pharmacist. 
Če se to zgodi, še naprej jemljite zdravilo Zurampic in se posvetujte z zdravnikom ali farmacevtom.
Oval, 5.7 x 12.9 mm, blue tablets. 
modre tablete ovalne oblike, velikosti 5,7 x 12,9 mm
Zurampic should not be restarted without another explanation for the serum creatinine abnormalities. 
Zdravljenja z zdravilom Zurampic se ne sme znova uvesti, če ni kakšne druge razlage za ugotovljene nenormalne vrednosti kreatinina v serumu.
Effect of other medicinal products on lesinurad 
Vpliv drugih zdravil na lesinurad:
Pre-existing cardiovascular disease 
Že obstoječa srčno-žilna bolezen
Lesinurad is a mild to moderate inducer of CYP3A and therefore may lower plasma concentrations of some hormonal contraceptives, thereby decreasing contraceptive effectiveness (see sections 4.4 and 
Lesinurad blago do zmerno inducira CYP3A in zato lahko zniža plazemsko koncentracijo nekaterih hormonskih kontraceptivov ter tako zmanjša njihovo kontracepcijsko učinkovitost (glejte poglavji 4.4 in 4.6).
In rats, there was no effect on mating or fertility with lesinurad (see section 5.3). 
Pri podganah lesinurad ni vplival na parjenje ali plodnost (glejte poglavje 5.3).
Some people may have more gout attacks (gout flares) when they start using Zurampic and during the first weeks or months of treatment. 
Nekateri bolniki imajo lahko po začetku uporabe zdravila Zurampic in v prvih tednih ali mesecih zdravljenja več napadov protina.
If you stop taking Zurampic Do not stop taking Zurampic without the advice of your doctor even if you feel better. 
Če ste prenehali jemati zdravilo Zurampic Tudi če se počutite bolje, ne prenehajte jemati zdravila Zurampic, če vam tega ne svetuje zdravnik.
Mild to moderate induction of CYP3A by lesinurad may reduce plasma exposures of co-administered medicines that are sensitive substrates of CYP3A. 
Blaga do zmerna indukcija CYP3A, ki jo povzroči lesinurad, lahko zmanjša plazemsko izpostavljenost sočasno uporabljenim zdravilom, ki so občutljivi substrati CYP3A.
The target serum uric acid level is less than 6 mg/dL (360 µmol/L). 
Ciljna koncentracija sečne kisline v serumu je manj kot 6 mg/dl (360 µmol/l).
Lesinurad should only be used in combination with a xanthine oxidase inhibitor because combination use reduces the amount of uric acid available for excretion and decreases the risk of renal-related events. 
Lesinurad se sme uporabljati samo v kombinaciji z zaviralcem ksantin-oksidaze, ker kombinirana uporaba zmanjša količino sečne kisline, ki je na voljo za izločanje in zmanjša tveganje za ledvične dogodke.
If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking Zurampic. 
Če kaj od naštetega velja za vas (ali če niste prepričani), se pred jemanjem zdravila Zurampic posvetujte z zdravnikom ali farmacevtom.
Other moderate CYP2C9 inhibitors, such as amiodarone, would also be expected to affect lesinurad pharmacokinetics to a similar degree. 
Pričakovati je mogoče, da v podobni meri vplivajo na farmakokinetiko lesinurada tudi drugi zmerni zaviralci CYP2C9, npr. amiodaron.
--o-- Placebo + Allopurinol, 
Terapevtska skupina: --o-- Placebo + Alopurinol,
All patients with a Major Adverse Cardiovascular Event treated with Zurampic 200 mg had a history of heart failure, stroke or myocardial infarction. 
Vsi bolniki, ki se jim je pojavil večji srčno-žilni neželen učinek in so bili zdravljeni z 200 mg zdravila Zurampic, so imeli v anamnezi srčno popuščanje, možgansko kap ali miokardni infarkt.
Uncommon - may affect up to 1 in 100 people - kidney stones, - dehydration (loss of too much fluid from your body). 
Občasni - pojavijo se lahko pri največ 1 od 100 bolnikov - ledvični kamni, - dehidracija (prekomerna izguba tekočine iz telesa).
BLISTER NON-PERFORATED (10 TABLETS) BLISTER PERFORATED UNIT DOSE CALENDAR BLISTER (14 TABLETS) 
PRETISNI OMOT, NEPERFORIRANI (10 TABLET) PRETISNI OMOT, PERFORIRANI, ZA ENKRATNI ODMEREK KOLEDARSKI PRETISNI OMOT (14 TABLET)
If you stop taking your xanthine oxidase inhibitor medicine, you must also stop taking Zurampic. 
Če ste prenehali jemati zdravilo, ki zavira ksantin-oksidazo, morate prenehati jemati tudi zdravilo Zurampic.
Driving and using machines Zurampic is not expected to affect you being able to drive a car or use any tools or machines. 
Vpliv na sposobnost upravljanja vozil in strojev Ni pričakovati, da bi zdravilo Zurampic vplivalo na vašo sposobnost za upravljanje vozil ali strojev.
Lesinurad is a selective uric acid reabsorption inhibitor that inhibits uric acid transporter URAT1. 
Lesinurad je selektiven zaviralec reabsorpcije sečne kisline, ki zavira prenašalca sečne kisline URAT1.
Lesinurad exposure is expected to decrease when it is co-administered with inducers of CYP2C9 (e.g. carbamazepine, a moderate CYP2C9 inducer). 
Pričakovati je, da se izpostavljenost lesinuradu zmanjša, če je uporabljen sočasno z induktorji CYP2C9 (npr. s karbamazepinom, ki je zmeren induktor CYP2C9).
Based on these studies, Zurampic is only recommended at a dose of 200 mg once daily in combination with a xanthine oxidase inhibitor (see sections 4.2 and 4.4). 
Na podlagi teh študij je edini priporočeni odmerek zdravila Zurampic 200 mg enkrat na dan v kombinaciji z zaviralcem ksantin-oksidaze (glejte poglavji 4.2 in 4.4).
Mean sUA reductions following Zurampic 200 mg administration alone were approximately 46% and 26% at 6 hours and 24 hours post-dose, respectively. 
Povprečno znižanje SKs po uporabi 200 mg zdravila Zurampic samega je bilo 6 ur po uporabi približno 46 % in 24 ur po uporabi približno 26 %.